Desirudin is a recombinant form of hirudin, the anticoagulant protein of the medicinal leech. It blocks thrombin, the enzyme at the center of blood clotting. It was approved in the United States as Iprivask and is now listed as discontinued. This guide covers its structure, mechanism, labeled use, key trial and warnings. Sources were checked on November 17, 2026.
Quick answer: Desirudin is a direct thrombin inhibitor made in yeast. Its label covered prevention of deep vein thrombosis in patients having elective hip replacement surgery. The label carries a boxed warning about spinal or epidural blood clots, which can cause lasting paralysis. Bleeding was the most common reaction.
Vitrapep does not sell desirudin; this page is a reference summary of published research and regulatory information.
What is desirudin?
The Iprivask label calls desirudin “a direct inhibitor of human thrombin.” It explains that its structure is similar to hirudin, “the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis.” Hirudin is described as “a single polypeptide chain of 65 amino acids residues” that “contains three disulfide bridges” (Iprivask label, 2014).
Desirudin is made in yeast, Saccharomyces cerevisiae, by recombinant DNA technology. It differs from natural hirudin by lacking a sulfate group on tyrosine 63. MeSH text in PubChem says it has the same sequence as natural hirudin variant 1 (PubChem CID 16129703). With 65 amino acids, it sits at the border between peptide and small protein. Our peptide versus protein guide explains that line.
The label and PubChem both give the formula C287H440N80O110S6. The label lists a molecular weight of 6,963.52, and PubChem lists 6,963. Drugs@FDA lists the original approval of Iprivask (application 021271) on April 4, 2003. It notes that this former NDA was deemed a biologics license application (BLA) on March 23, 2020 (Drugs@FDA).
Desirudin: key facts
| Fact | Detail |
|---|---|
| Structure type | Recombinant hirudin: single chain of 65 amino acids with three disulfide bridges; made in yeast |
| Class | Direct thrombin inhibitor (anticoagulant) |
| Molecular formula | C287H440N80O110S6 |
| Molecular weight | 6,963 g/mol (6,963.52 per label) |
| First FDA approval | April 4, 2003 (Iprivask, application 021271; deemed a BLA in 2020) |
| Brand names (US) | Iprivask (Bausch Health US); listed as discontinued |
How does desirudin work?
Thrombin is a key clotting enzyme. The label states that “desirudin is a direct inhibitor of free circulating and clot-bound thrombin.” It adds that “one molecule of desirudin binds to one molecule of thrombin and thereby blocks the thrombogenic activity of thrombin” (Iprivask label, 2014).
NCI Thesaurus text in PubChem calls it “a selective and almost irreversible inhibitor of thrombin, both free and clot-bound, by blocking its active site.” The label notes that all thrombin-dependent clotting tests are affected, and that the aPTT test tracks its activity. Our bivalirudin guide covers another peptide that blocks thrombin.
What is desirudin approved for?
The Iprivask label covers “the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.” Prophylaxis means prevention. Deep vein thrombosis is a clot in a deep vein, usually in the leg.
The product is now listed as discontinued, so this describes the last approved label rather than current practice.
What did the key trials show?
Desirudin versus enoxaparin. The main human trial was a multicenter, randomized, double-blind study at 31 centers in 10 European countries. It compared desirudin with enoxaparin, a low-molecular-weight heparin, after primary total hip replacement. Of 2,079 patients randomized, 1,587 were included in the main efficacy analysis. Clots were confirmed by venography, an X-ray of the veins.
Proximal deep vein thrombosis, the type closer to the trunk, occurred in 4.5% of desirudin patients and 7.5% of enoxaparin patients. That is a 40.3% relative reduction (P = 0.01). Any deep vein thrombosis occurred in 18.4% versus 25.5% (P = 0.001). The authors reported similar safety profiles in the two groups (Eriksson et al., 1997a).
Desirudin versus heparin. A double-blind, multicenter human trial randomized 445 hip replacement patients to desirudin or unfractionated heparin. In 351 evaluable patients, any deep vein thrombosis occurred in 7% on desirudin versus 23% on heparin (p < 0.0001). Proximal deep vein thrombosis occurred in 3% versus 16%. Bleeding did not differ significantly between groups (Eriksson et al., 1997b). The label reports the same trial as 7.5% versus 23.2%.
What side effects does the label list?
The Iprivask label carries a boxed warning titled “Spinal/epidural hematomas.” It warns that patients receiving neuraxial anesthesia or spinal puncture while anticoagulated may develop a spinal or epidural hematoma. Such a bleed “can result in long-term or permanent paralysis.” The risk may rise with indwelling spinal catheters and with drugs that affect clotting, such as NSAIDs.
The label states that the most common adverse reaction was hemorrhage, at 33%. Other reactions at 2% or more were site mass, wound secretion, anemia, deep thrombophlebitis and nausea. In hip replacement trials, any hemorrhage occurred in 30% on Iprivask, 22% on heparin and 33% on enoxaparin. Serious hemorrhage occurred in 3%, 3% and 2%.
Other warnings cover hemorrhagic events, a higher bleeding risk in kidney impairment and antibodies on re-exposure. The label notes that fatal anaphylactic reactions have been reported during hirudin therapy (Iprivask label, 2014).
What is desirudin’s regulatory status, and how is it used in research?
FDA records give the path to approval. The investigational exemption took effect on May 17, 1990, and the application was submitted on June 28, 2000. Approval followed on April 4, 2003, a review period of 4,707 days in total (Federal Register, 2004).
Drugs@FDA lists Iprivask’s marketing status as discontinued. Its most recent label there dates from November 2014. FDA’s Purple Book lists Iprivask as a 351(a) biologic from Bausch Health US, LLC. Its marketing status there is “Disc” (FDA Purple Book).
DailyMed’s labeling service returned no current desirudin labels when we checked. We did not find an FDA notice giving the date or reason for discontinuation, and we found no FDA safety communication. LiverTox, quoted in PubChem, says desirudin has not been linked to liver enzyme elevations or clinically apparent liver injury. A later sponsor, Canyon Pharmaceuticals, completed a phase 4 safety study of 516 patients (NCT00913133). The research summarized here is clinical, in human patients. We found no documented role as a routine laboratory reagent in the sources we checked.
Frequently asked questions about desirudin
Is desirudin a peptide?
Yes, in the broad sense. It is a single chain of 65 amino acids, large enough that the label calls its structure protein-like.
When was desirudin approved?
Drugs@FDA lists the original approval of Iprivask on April 4, 2003.
Where does desirudin come from?
It is a recombinant copy of hirudin, the anticoagulant of the medicinal leech, made in yeast. It lacks one sulfate group found on natural hirudin.
Is Iprivask still available?
Drugs@FDA and the Purple Book both list it as discontinued.
Does desirudin have a boxed warning?
Yes. It warns of spinal or epidural hematomas, which can cause long-term or permanent paralysis, with neuraxial anesthesia or spinal puncture.
What to know now
- Structure: recombinant hirudin; 65 amino acids, three disulfide bridges; about 6,963.
- Approval: Iprivask, April 4, 2003; deemed a BLA in 2020; now listed as discontinued.
- Mechanism: direct, one-to-one inhibitor of free and clot-bound thrombin.
- Label use: prevention of deep vein thrombosis in elective hip replacement.
- Evidence: proximal DVT 4.5% versus 7.5% with enoxaparin.
- Safety: boxed warning for spinal or epidural hematoma; hemorrhage most common.
What we’re watching
Any FDA finding on why Iprivask left the market; we found none. Any new desirudin label on DailyMed. Related guides: bivalirudin, eptifibatide and peptides versus proteins.